Gothenburg university, University in Gothenburg, Sweden

The findings of a new study suggest that nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumours sensitive to a type of immunotherapy drug called a checkpoint inhibitor.This is according to a new study published in Cancer Immunology Research by researchers at Karolinska Institutet in Sweden.Treatments for various forms of cancer have improved considerably over recent years thanks to a type of drug called a checkpoint inhibitor, which helps the immune system's T cells to attack the cancer cells.However, even though some patients respond extremely well to treatment, a large proportion only sees temporary improvement, if any. Scientists are devoting considerable energy to understanding why this is so and to combining checkpoint inhibitors with other therapies in order to increase the cancer survival rate.A new cancer therapyResearchers from Karolinska Institutet show how a form of round nanoparticles called exosomes or extracellular vesicles is a promising path to follow."Is seems that the vesicles make the tumour immunologically active so that the checkpoint therapy can gain purchase and start to work," says the study's last author Susanne Gabrielsson, professor at the Department of Medicine (Solna), Karolinska Institutet. "These results give support to the further development of extracellular vesicles as a new cancer therapy."Extracellular vesicles are sometimes referred to as the body's messengers. They are membrane-bound nano-scale bubbles that cells can send to each other to exchange information. Vesicles from tumour cells, for instance, can switch off the immune system so that cancer can spread, while vesicles from immune cells can activate an immune response.Can activate immune cellsIn earlier studies, KI researchers have shown that a certain type of extracellular vesicle from immune cells can activate immune T cells and reduce tumour growth in mice. In the present study, they examined how these vesicles function in a mouse model of skin cancer that is resistant to checkpoint inhibitor therapy.The extracellular vesicles used in the study were isolated from the mice's own immune cells (dendritic cells). In this case, a cancer-specific protein called ovalbumin and a molecule called alpha-Galactosylceramide were then added, both of which stimulate T cells and natural killer cells.When the vesicles were introduced into mice therapeutically to treat their tumours or prophylactically before their tumours started to develop, they activated their immune systems to produce a strong T-cell response to the cancer protein. The same effect was not achieved if the animals were only given checkpoint inhibitors, and was most pronounced in animals that received a combination of vesicles and checkpoint therapy.However, the researchers observed no effect on survival when the animals received the vesicle-checkpoint combination therapy compared with vesicles alone, and believe that the duration of the experiment was possibly too short for the activated immune system to affect the tumours. When the treatments were given prophylactically to mice, which gives a longer duration of action, the mice that received the combination treatment showed greater survival than those that only received vesicles.Tested on human patientsOther researchers tried giving extracellular vesicles from immune cells to human patients as a cancer therapy already back in 2005. In these studies, the vesicles have proved safe but only minimally effective. Professor Gabrielsson believes that this was because the experiments were conducted too early before scientists knew what molecules the vesicles should contain to be effective, something to which her team has devoted considerable effort. They are also trying to simplify the manufacture of extracellular vesicles."Our aim is to be able to use cell lines instead of having to take the patient's own cells," she says. "This will mean that the vesicles can be prepared in advance and frozen until needed. We also believe that variants of the treatment could be used for other forms of cancer and other diseases."( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Gothenburg UniversityFOLLOW

Gothenburg university, Latest News

An international study published in Heart reports found that patients with heart failure frequently suffer co-morbidities, putting significant pressure ... ...

Stockholm, Feb 11 Swedish police has said that they had launched an operation to bolster security in the ... ...

The discovery of deposits of large quantities of rare earths in Sweden marks the "beginning of the end of ... ...

Stockholm, Jan 28 Judicial cooperation in the fight against organised crime topped the agenda of an informal meeting ... ...

Stockholm, Jan 28 A damaged nuclear reactor in Sweden that was due to be restarted in February has ... ...

Stockholm, Jan 25 The Swedish government has announced an "international information campaign", which it expects to discourage refugees ... ...

Washington, Dec 24 Ukraine put India-US ties to the test in 2022. The relationship had been sailing high ... ...

The findings of a new study suggest that nano-sized membrane bubbles known as extracellular vesicles activate the immune system ... ...